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Abstract
Background: Previous studies have shown that lesions in proximal left anterior descending coronary artery (LAD) may
develop more restenosis after balloon angioplasty than lesions in other coronary segments. However, stenting seems to have
reduced this gap. In this study, we compared outcomes of percutaneous coronary intervention (PCI) on proximal LAD versus
proximal left circumflex (LCX) or right coronary artery (RCA) and proximal versus non-proximal LAD.
Methods: From 1737 patients undergoing PCI between March 2004 and 2005, those with cardiogenic shock, primary PCI,
total occlusions, and multivessel or multi-lesion PCI were excluded. Baseline characteristics and in-hospital outcomes were
compared in 408 patients with PCI on proximal LAD versus 133 patients with PCI on proximal LCX/RCA (study I) and 244
patients with PCI on non-proximal LAD (study II). From our study populations, 449 patients in study I and 549 patients in study
II participated in complete follow-up programs, and long-term PCI outcomes were compared within these groups. The
statistical methods included Chi-square or Fisher's exact test, student's t-test, stratification methods, multivariate logistic
regression and Cox proportional hazards model.
Results: In the proximal LAD vs. proximal LCX/RCA groups, smoking and multivessel disease were less frequent and drug-
eluting stents were used more often (p = 0.01, p < 0.001, and p < 0.001, respectively). Patients had longer and smaller-diameter
stents (p = 0.009, p < 0.001, respectively). In the proximal vs. non-proximal LAD groups, multivessel disease was less frequent
(p = 0.05). Patients had larger reference vessel diameters (p < 0.001) and were more frequently treated with stents, especially
direct stenting technique (p < 0.001). Angiographic success rate was higher in the proximal LAD versus proximal LCX/RCA
and non-proximal LAD groups (p = 0.004 and p = 0.05, respectively). In long-term follow-up, major adverse cardiac events
showed no difference. After statistical adjustment for significant demographic, angiographic or procedural characteristics, long-
term PCI outcomes were still similar in the proximal LAD versus proximal LCX/RCA and non-proximal LAD groups.
Conclusion: Despite the known worse prognosis of proximal LAD lesions, in the era of stenting, our long-term outcomes
were similar in patients with PCI on proximal LAD versus proximal LCX/RCA and non-proximal LAD. Furthermore, we had
better angiographic success rates in patients with PCI on proximal LAD.
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Background
Stenosis of the proximal segment of the left anterior
descending coronary artery (LAD) is a special subgroup of
coronary artery disease (CAD), given the high-risk profile
that these lesions have alone or in the context of multives-
sel disease [1,2]. Patients with proximal LAD occlusion in
association with low left ventricular ejection fraction have
been reported to have 19-fold higher mortality than the
general population [3].
The data from previous studies suggest that the outcome
after revascularization depends on the distribution of pre-
revascularization coronary artery disease. In that regard,
the severity and location of LAD involvement have been
identified as important determinants of outcome in
patients with CAD [4]. This lesion carries a high risk of res-
tenosis after balloon angioplasty with reported patency
rate at six month-follow-up of approximately 75% [5].
However, some studies have shown that stenting may
reduce the rate of restenosis in these lesions in compari-
son with balloon angioplasty [6]. Specifically, drug-elut-
ing stents have been shown to be related to significantly
reduced restenosis rates compared to bare metal stents
[7,8].
Numerous studies have investigated the outcome of per-
cutaneous coronary intervention (PCI) and bypass sur-
gery in patients with LAD stenosis [9-11]. Generally, the
presence of a proximal LAD stenosis has swayed the cardi-
ologists to refer the patients to coronary artery bypass
grafting (CABG) presuming these lesions have an overall
higher rate of restenosis than proximal left circumflex or
right coronary artery [12]. However, according to the
American College of Cardiology/American Heart Associa-
tion, only type B2/C lesions of the LAD carry a high risk of
target vessel revascularization (TVR) and morbidity [13]
and surgery has been proposed as a better option only for
such lesions [14]. According to the 2003 report from the
Iranian Statistical Center, 14100 PCI procedures were per-
formed in 50 hospitals in Iran. Of these, approximately
1700 procedures were carried out in Tehran Heart Center
(THC). Because of the clinical significance of the lesions
located in proximal LAD, our objective in this study was
to evaluate the procedural results, in-hospital and long-
term clinical outcomes of PCI on proximal LAD, proximal




From a total of 1737 consecutive patients undergoing PCI
at THC between March 2004 and March 2005, a patient
cohort with PCI for de novo narrowing in the proximal
segments of coronary arteries or non-proximal LAD were
included in the study. Patients with cardiogenic shock,
primary PCI, total occlusions, and multivessel or multi-
lesion PCI were excluded. Among the 785 remaining
patients: 408 had PCI on proximal LAD, 133 underwent
PCI on proximal LCX or RCA, and 244 patients were
treated with PCI on non-proximal LAD. In study I (n =
541), we compared the outcomes of PCI on proximal LAD
versus proximal LCX/RCA. In study II (n = 652), the out-
come of PCI on proximal LAD versus non-proximal LAD
were compared. Baseline, clinical, angiographic, and pro-
cedural characteristics plus in-hospital outcomes were
obtained by research physicians and entered into a com-
puterized database by computer operators. Finally, 449
patients in study I and 549 patients in study II agreed to
participate in follow-up programs. They were monitored
by cardiologists 1, 5, and 9 months post angioplasty and
once a year thereafter. Patient follow up was done in the
clinic or by formal telephone interviews. Clinical data
obtained were: major adverse cardiac events (MACE),
including cardiac death, non-fatal myocardial infarction
(MI), and TVR (CABG or repeated PCI). The data were
recorded in data sheets and later transferred into a compu-
terized database. This study was approved by the THC Eth-
ics Committee. Informed consent was obtained from
patients before enrolment into this study.
Definitions
Patients already taking hypertensive medication or those
whose average of two blood pressure readings at least five
minutes apart in the sitting posture was ≥ 140/90 mmHg
were labeled as hypertensive [15]. Patients with a history
of taking antihyperlipidemic drugs, total cholesterol ≥
200 mg/dl or low density lipoprotein ≥ 130 mg/dl were
defined as hypercholestrolemic [16]. Diabetes mellitus
was diagnosed to be present if a patient had a definite his-
tory of treated diabetes, fasting plasma glucose ≥ 126 mg/
dl or two-hour post-load glucose ≥ 200 mg/dl, based on
the guidelines of the American Diabetes Association [17].
Angina symptoms were defined according to the classifi-
cation of the Canadian Cardiovascular Society [18].
Lesion types were noted according to the American Col-
lege of Cardiology/American Heart Association (ACC/
AHA) lesion characteristics classification [19]. Left ven-
tricular ejection fraction was obtained from cardiac cathe-
terization ventriculograms. Q wave MI was defined as the
presence of new Q waves in post-procedure electrocardio-
grams with a 3-fold increase in MB fraction of creatinine
kinase. Non-Q wave MI was defined as a 3-fold increase in
MB fraction of creatinine kinase without the development
of new Q waves [20]. Angiographic success was defined as
residual stenosis <20% for stenting and <50% for balloon
angioplasty plus normal Thrombolysis in Myocardial Inf-
arction (TIMI) 3 flow. Procedural success was defined as
angiographic success without major complications
(death, MI, emergency CABG or PCI) during hospitaliza-
tion [19]. Major adverse cardiac events were defined as theBMC Cardiovascular Disorders 2007, 7:7 http://www.biomedcentral.com/1471-2261/7/7
Page 3 of 8
(page number not for citation purposes)
presence of cardiac death, MI, and TVR during follow-up.
TVR was defined as ischemia-driven repeat percutaneous
intervention or bypass surgery of the target vessel. Target
lesion revascularization (TLR) was defined as ischemia-
driven repeat percutaneous intervention of the target
lesion or bypass surgery of the target vessel [21]. Proximal
stenosis was defined as stenosis located between the ori-
gin of the vessel to the takeoff of the first side branch (first
diagonal branch for LAD).
Coronary procedures
Patients received 325 mg of Aspirin before the procedure,
which was continued indefinitely. Coronary stenting was
performed by standard methods. After stent placement,
ticlopidine (250 mg twice daily) or clopidogrel (75 mg
once daily) was given routinely for 4 weeks for bare metal
stents and 6 to 12 months for drug-eluting stents. Glyco-
protein IIb/IIIa blocker was not used in any patient. Ang-
iographic findings such as vessel dimensions, pre-and
post-procedural stenoses, lesion length, and TIMI flow
grade were determined by visual estimation using the
guiding catheter as a reference object for calibration. The
angiographic characteristics were also further analyzed by
an independent interventional cardiologist not involved
in the procedure and checked for inter-observer agree-
ment (kappa coefficient = 0.91, 95% CI = 0.85–0.97).
Statistical analysis
Statistical testing was performed by chi-square test or
Fisher's exact test (2-tailed) for categorical variables. Stu-
dent's t-test was used for comparison of continuous varia-
bles. Because of the imbalances in some baseline
characteristics, the main study results were confirmed by
means of stratified analyses and multivariate logistic
regression models. Stratification was performed for varia-
bles that either had significant imbalance between the
groups (p < 0.05), or were clinically important. These var-
iables included sex, diabetes mellitus, prior PCI, use of
drug-eluting stents, angulated segments, stent length, and
stent diameter. Furthermore, we constructed multivariate
logistic regression models with selected variables that had
p values < 0.05 in univariate analysis (sex and use of drug-
eluting stents were also included). The p values of these
variables are marked in bold l in tables 1 and 2. Long-term
MACE modeling was performed with Cox proportional
hazards model. The statistical analyses were performed
with SAS software version 9.1. Differences were consid-
ered statistically significant at p values < 0.05.
Results
Baseline characteristics
Table 1 represents selected baseline characteristics of
patients treated for proximal stenoses of major epicardial
arteries and non-proximal LAD. Current smoking and
prior non-target vessel PCI had a lower frequency in
patients with PCI on proximal LAD versus LCX or RCA.
However, in patients with PCI on proximal versus non-
proximal LAD, the baseline demographic characteristics
did not differ. Mean Ejection Fraction was 53.54 ± 9.45%
in the proximal LAD versus 53.12 ± 10.24% and 54.35 ±
9.22% in the proximal LCX/RCA and non-proximal LAD
groups (p = NS), respectively. In the proximal LAD versus
proximal LCX/RCA and non-proximal LAD, the frequency
of unstable angina (33.7% vs. 34.8% and 33.7%) and
prior MI (33.8% vs. 28.6% and 29.5%) had no statistically
significant difference (P = NS).
Angiographic and procedural characteristics (Table 2)
Frequency of type B2/C lesions was similar in the proxi-
mal LAD vs. proximal LCX/RCA and non-proximal LAD
Table 1: Selected baseline characteristics in the Proximal LAD versus Proximal LCX/RCA and Non-proximal LAD groups
Proximal LAD n = 408 Proximal LCX/
RCA n = 133
P value (study I) * Non-proximal 
LAD n = 244
P value (study II) **
Age(yrs) (mean ± SD) 55.36 ± 10.87 56.94 ± 9.7 0.14 55.6 ± 10.88 0.78
Male 285(69.9%) 104(78.2%) 0.06 163(66.8%) 0.41
Diabetes Mellitus 76(19.1%) 33(25.4%) 0. 12 58 (24%) 0.14
Family history of CAD 89(21.8%) 21(15.8%) 0.13 54(22.1%) 0.91
hypercholesterolemia 171(43%) 59(45.4%) 0.63 107(44.2%) 0.76
Current smoker 157(38.5%) 68(51.1%) 0.01 86(35.2%) 0.41
hypertension 132(33.2%) 38(29.2%) 0.4 92(38%) 0.21
Myocardial infarction 138 (33.8%) 38 (28.6%) 0.26 72 (29.5%) 0.25
Prior PCI (Non-target vessel) 15(3.7%) 12(9%) 0.01 7(2.9%) 0.58
Prior CABG 2(0.5%) 2(1.5%) 0.24 1(0.4%) >0.999
CAD = coronary artery disease
PCI = percutaneous coronary intervention
CABG = coronary artery bypass grafting
* Proximal LAD group vs proximal LCX/RCA group
** Proximal LAD group vs non-proximal LAD group
Variables with p values that are marked in bold were entered into multivariate analysis.BMC Cardiovascular Disorders 2007, 7:7 http://www.biomedcentral.com/1471-2261/7/7
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groups: (42.8% vs.43.8% and 47.8, p = NS). Multivessel
disease and angulated segments were less frequent in the
proximal LAD group. In the proximal LAD versus proxi-
mal LCX/RCA group, lesions were longer (16.89 ± 8.1 mm
versus 14.68 ± 7.38 mm, p = 0.007) and had lower fre-
quency of proximal segment tortuosity (p = 0.03). How-
ever, percentage of lesions smaller than 3 mm in diameter
did not differ. On the other hand, in the proximal versus
non-proximal LAD group, expectedly, lesions had larger
reference vessel diameters. Stents were used in 99.8% of
patients in the proximal LAD versus 98.5% in the proxi-
mal LCX/RCA (p = NS) and 96.7% in the non-proximal
LAD groups (p = 0.002). Pre- and post-procedural stenosis
percentages did not differ significantly in the proximal
LAD versus proximal LCX/RCA and non-proximal LAD
groups (89.44 ± 8.65% versus 89.15 ± 9.37% and 89.96 ±
8.28%; 0.65 ± 3.24% versus 2.75 ± 13.69% and 1.11 ±
4.51%, p = NS). Patients with PCI on proximal LAD versus
proximal LCX/RCA were more commonly treated with
drug-eluting stents and had longer stents with smaller
diameters. Patients with proximal versus non-proximal
LAD stenosis were more often treated with stents, espe-
cially the direct stenting technique.
In-hospital and late clinical outcomes
In the proximal LAD group, procedures were angiograph-
ically successful in 100% of cases, which was significantly
greater than the other two groups. In-hospital events,
which occurred only as non-Q wave MI in our cohort,
were observed in 8 (2%) in the proximal LAD group,
while only 1 patient in the proximal LCX/RCA and non-
proximal LAD group (0.8% and 0.4% respectively) dis-
played such symptoms(P = NS). Procedural success rates
were similar in both comparisons (table 3). Mean follow-
up duration was 10.81 ± 3.69 months in total population.
Major adverse cardiac events at 9-month follow-up,
including cardiac death, MI, and TVR (CABG or repeated
PCI) were not significantly different in the proximal LAD
versus the other two groups (table 3). After stratification
for factors that either had significant imbalance between
the groups or were clinically important, the MACE rates in
the proximal LAD versus proximal LCX/RCA and non-
proximal LAD groups were still comparable (table 4).
Similarly, in multivariate logistic regression models, there
was no difference in MACE rates in the proximal LAD ver-
sus proximal LCX/RCA (p = 0.85, 95% CI = 0.19–3.89, OR
= 0.87) and proximal versus non-proximal LAD groups (p
= 0.66, 95% CI = 0.29–2.1, OR = 0.8). Cox proportional
hazards model also did not show any difference in MACE-
free survival rates at long-term follow-up (figure 1).
Discussion
The main finding that emerges from this study is that
long-term outcomes of PCI including MACE in patients
with proximal LAD stenosis are similar to patients with
proximal LCX or RCA and non-proximal LAD stenosis.
Also worth noting from our findings was that angio-
graphic success was higher in patients with proximal LAD
stenosis.
Management of proximal coronary artery disease is
important due to the large areas of myocardium that lie
downstream of the stenoses. The proximal LAD artery ste-
nosis represents the most important proximal site for
obstructive coronary artery after left main stem lesion dis-
ease, as it supplies 40%–50% of the total left ventricular
myocardium and could result in ischemia to a large area
of myocardium [22,23]. Moreover, Patients with a critical








LAD n = 244
P value (study II) **
Angiographic characteristics
Multivessel disease 110 (33.1%) 64 (61.5%) <0.001 85 (41.5%) 0.05
Type B2/C 169 (42.8%) 56 (43.8%) 0.85 110 (47.8%) 0.22
Angulated segments (>45°) 9 (2.2%) 18 (13.5%) <0.001 17 (7%) 0.003
Tubular lesions 221(54.2%) 53 (39.8%) 0.004 118 (48.4%) 0.15
Proximal tortuoisity 2 (0.5%) 4 (3%) 0.035 2 (0.8%) 0.6
RVD (<3 mm) 85 (21.6%) 21 (16.2%) 0.18 109 (46.6%) <0.001
Procedural characteristics
Direct stenting technique 251(61.5%) 82 (62.6%) 0.33 122(50.4%) <0.001
Drug-eluting stents 97 (24.3%) 9 (7.2%) <0.001 39 (17.2%) 0.079
Stent length(mm), mean ± SD 18.48 ± 6.79 16.68 ± 6.69 0.009 18.54 ± 6.77 0.9
Stent diameter(mm), mean ± SD 3.08 ± 6.79 3.23 ± 0.39 <0.001 2.88 ± 6.76 <0.001
RVD = reference vessel diameter (estimated visually)
* Proximal LAD group vs Proximal LCX/RCA group
** Proximal LAD group vs Non-proximal LAD group
Variables with p values that are marked in bold were entered into multivariate analysis.BMC Cardiovascular Disorders 2007, 7:7 http://www.biomedcentral.com/1471-2261/7/7
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(95% CI) Study II
Sex
male 7/235 (3.2) 3/88(3.4) 0.9(0.2–3.4) 9/143(6.3) 0.5 (0.2–1.2)
female 4/103 (3.9) 0/23 - 3/68(4.4) 0.9(0.2–4.0)
Diabetes mellitus
Yes 1/66(1.5) 0/28 - 4/52(7.7) 0.2(0.1–1.7)
No 10/373(3.6) 3/82(3.7) 1.0(0.3–3.8) 8/157(5.1) 0.7(0.3–1.9)
Prior PCI
Yes 0/12 0/11 - 0/6 -
No 11/326(3.3) 3/100(3.0) 1.1(0.4–4.1) 12/205(5.9) 0.6(0.2–1.3)
Drug-eluting stents
Yes 2/83(2.4) 0/6 - 1/37(2.7) 0.8(0.1–9.5)
No 9/260(3.5) 3/100(3.0) 1.2(0.4–4.5) 11/169(6.5) 0.6(0.2–1.4)
Angulated segments
Yes 0/7 0/16 - 0/15 -
No 11/331 (3.3) 3/95(3.2) 1.1(0.3–3.8) 12/196(6.2) 0.5(0.3–1.2)
Stent length
<20 mm 10/270(3.7) 3/94(3.2) 1.2(0.4–4.3) 8/146(5.4) 0.7(0.3–1.8)
>20 mm 1/68(1.5) 0/1 - 4/55(7.3) 0.2(0.1–1.7)
Stent diameter
<3 mm 6/73(8.2) 0/15 - 7/97(7.2) 1.4(0.4–4.4)
>3 mm 5/260(1.9) 3/98(3.1) 0.6(0.1–2.6) 5/100(5.0) 0.4(0.1–1.4)
PCI = percutaneous coronary intervention
CI = Confidence Interval
* Odds Ratio for MACE in the Proximal LAD vs. Proximal LCX/RCA group
** Odds Ratio for MACE in the Proximal LAD vs. Non-proximal LAD group
Table 3: In-hospital and late outcomes of PCI in the Proximal LAD versus Proximal LCX/RCA and Non-proximal LAD groups
Proximal LAD n (%) Proximal LCX/
RCA n (%)
P value (study I) * Non-proximal 
LAD n (%)
P value (study II) **
In-hospital outcomes n = 408 n = 133 n = 244
Angiographic Success 408 (100%) 129 (97%) 0.004 241 (98.8%) 0.05
Procedural Success 400 (98%) 128 (96.2%) 0.10 240 (98.4%) >0.999
In-hospital Events 8 (2%) 1 (0.8%) 0.45 1 (0.4%) 0.27
9-month follow-up n = 338 n = 111 n = 211
Major adverse cardiac events 11 (3.3%) 3 (2.7%) >0.999 12 (5.7%) 0.17
Cardiac death 1 (0.3%) 1 (0.9%) 0.43 2 (0.9%) 0.56
Non-fatal MI 4(1.2%) 1 (0.9%) >0.999 2 (0.9%) >0.999
TVR 6 (1.8%) 2 (1.8%) >0.999 7 (3.3%) 0.17
TLR 2 (0.6%) 1 (0.9%) 0.57 2 (0.9%) 0.63
CABG 4 (1.2%) 1 (0.9%) >0.999 5 (2.4%) 0.29
MI = myocardial infarction
CABG = coronary artery bypass grafting
TVR = target vessel revascularization
TLR = target lesion revascularization
* Proximal LAD group vs Proximal LCX/RCA group
** Proximal LAD group vs Non-proximal LAD groupBMC Cardiovascular Disorders 2007, 7:7 http://www.biomedcentral.com/1471-2261/7/7
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stenosis of the proximal LAD segment are particularly
prone to adverse effects of MI and, therefore, require a safe
and long-term effective method of treatment [24].
Previous studies have demonstrated that interventional
treatment produces are more beneficial than pharmaco-
logical treatment in severe proximal LAD artery disease
[6]. However, The results of nonstenting PCI to proximal
LAD stenoses has been less satisfactory than procedures in
the proximal right/circumflex coronary arteries due to
higher rates of restenosis in this area [12,25,26]. Stenting
leads to better clinical outcomes than percutaneous trans-
luminal coronary angioplasty in the treatment of isolated
lesions of proximal LAD by reducing the risk of restenosis
by about 50% [3]. In fact, stenting of lesions in the proxi-
mal LAD is as effective and safe as treatment of lesions
located in distal LAD. Therefore, in the current stenting
era, location of the lesion in the LAD is not predictive of
worse outcome. Furthermore, when stenting is feasible, it
may not be taken into account in the choice of revascular-
ization strategy [27]. However, the re-intervention rates
have been higher after bare-metal stenting than bypass
surgery of the proximal LAD [28]. With the advent of
drug-eluting stents, a reduction has been achieved in rest-
enosis rates after stenting in proximal LAD. This in turn
has narrowed the "reintervention gap" between drug-elut-
ing stents enough to eliminate the major advantage of
bypass surgery for the treatment of LAD disease [7].
In our study, no significant difference was observed in
rates of major adverse cardiac events during long-term fol-
low-up in the proximal LAD versus the other two groups.
Even after adjusting for factors such as stents, particularly
drug-eluting stents, which were used most frequently in
the proximal LAD group, no statistical difference was
detectible. MACE-free survival rates were also similar
between the groups (figure 1). Before our study, Ashby et
al had studied the outcomes of stenting in proximal LAD
versus proximal LCX/RCA [12]. In their study, multivari-
ate analysis was conducted to adjust these groups for
some baseline differences. However, the main endpoint
of this study i.e. rate of TLR, was still similar in both
groups in patients treated with stents. Before that, The
Stent Restenosis (STRESS) study had shown that irrespec-
tive of the procedure used (balloon angioplasty or stent-
ing), the most important predictors of the larger luminal
diameter at follow-up were the size of the luminal diame-
ter after the procedure, the initial reference vessel diame-
ter, and the location of a lesion in a vessel other than LAD
[29].
As a secondary aim, we found that angiographic success
rate was higher in patients with proximal LAD stenoses.
This may be attributed to better accessibility of lesions and
higher frequency of stent use in the proximal LAD group.
However, because of the paucity of procedural failure
rates, this effect could not be proven by means of statisti-
cal analyses.
One of the limitations of this study was the relatively
small sample size of patients who had developed compli-
cations, which made it difficult to determine the predic-
tors of MACE from the multivariate analysis. On the other
hand, we had to exclude patients with multi-lesion or
multivessel percutaneous coronary intervention, because
otherwise we would not have been able to attribute MACE
to a particular lesion site.
Conclusion
In our study, there was no difference in the short- and
long-term clinical outcomes of PCI (MACE and its com-
ponents) on proximal LAD versus proximal parts of other
major epicardial arteries and non-proximal LAD. How-
ever, acute angiographic success rate was higher in
patients with proximal LAD lesions. After adjusting the
groups for significant baseline differences, there was still
no difference in clinical outcomes between these groups.
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